Derek Maetzold Sells 5,115 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 5,115 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $40.05, for a total value of $204,855.75. Following the transaction, the insider directly owned 45,822 shares in the company, valued at $1,835,171.10. This represents a 10.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Castle Biosciences Price Performance

Castle Biosciences stock traded up $0.25 during midday trading on Wednesday, reaching $40.18. The company’s stock had a trading volume of 338,008 shares, compared to its average volume of 458,690. The firm has a market capitalization of $1.17 billion, a PE ratio of -89.22 and a beta of 1.12. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $40.51. The stock’s 50 day simple moving average is $27.04 and its 200 day simple moving average is $21.83. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The business had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CSTL. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research report on Tuesday. Robert W. Baird raised their price objective on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. BTIG Research boosted their target price on Castle Biosciences from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.43.

Institutional Trading of Castle Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. raised its stake in Castle Biosciences by 0.5% in the 3rd quarter. Franklin Resources Inc. now owns 99,787 shares of the company’s stock valued at $2,272,000 after purchasing an additional 540 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after buying an additional 655 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Castle Biosciences by 1.0% during the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock valued at $1,439,000 after buying an additional 707 shares during the period. Inspire Investing LLC lifted its stake in shares of Castle Biosciences by 4.0% during the third quarter. Inspire Investing LLC now owns 19,887 shares of the company’s stock valued at $453,000 after buying an additional 770 shares during the period. Finally, CWM LLC grew its stake in Castle Biosciences by 80.6% in the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after acquiring an additional 853 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.